Home/Pipeline/Renal & Hepatic Denervation for Hypertension

Renal & Hepatic Denervation for Hypertension

Hypertension

FeasibilityActive

Key Facts

Indication

Hypertension

Phase

Feasibility

Status

Active

Company

Metavention

About Metavention

Metavention is a private, pre-revenue biotech company founded in 2010 and headquartered in Minneapolis, USA. It is advancing a catheter-based radiofrequency denervation platform targeting the sympathetic nervous system to treat hypertension and type 2 diabetes. The company is currently conducting multiple early-stage clinical studies (DeLIVER and MODUS) in the U.S., Australia, and New Zealand to evaluate the safety and performance of its iRF Denervation System for both renal and hepatic nerve ablation.

View full company profile

Therapeutic Areas

Cardiovascular Metabolic

Other Hypertension Drugs

Drug	Company	Phase	Status
Valsartan EP Impurity B	Synthink Research Chemicals	Reference Standard	Active
Norliqva® (Amlodipine Oral Solution)	CMP Pharma	Approved	Marketed
MVD-1 (SANA)	Eolo Pharma	Discovery	Active
Peregrine System Renal Denervation	Ablative Solutions	Phase 3	Active
Hypertension Program	Closed Loop Medicine	Development	Active
GMRx2	George Medicines	Phase 3	Active
High Blood Pressure Study	West Coast Research	Phase 3/4	Active
Biobeat Cuff‑less ABPM Patch	Biobeat	Commercial	Active
Zilebesiran (ALN-AGT)	Alnylam Pharmaceuticals	Phase 3	Active (KARDIA trials)
DehydraTECH-CBD	Lexaria Bioscience	Human Clinical	Active